Compound 17: Potent Dual URAT1/GLUT9 Inhibitor Data for Gout Treatment

Qian Yang published a dataset on figshare in May 2026 detailing the development of a novel thienopyrimidine derivative for gout and hyperuricemia treatment. The dataset likely contains results from the evaluation of 46 novel polycyclic pyrimidine derivatives, including compound 17's inhibitory activity and pharmacokinetic profiles. The dataset is 537.9 KB in size and is available in PDB format.

Use Cases

• Compare inhibitory potency based on IC50 values for URAT1 and GLUT9 mentioned in the description
• Analyze pharmacokinetic profiles based on bioavailability (F) data mentioned in the description
• Evaluate safety profiles based on acute toxicity test results mentioned in the description
• Model structure-activity relationships based on scaffold hopping and structure-guided design methods mentioned in the description

Strengths

• Includes specific IC50 values for URAT1 (4.01 μM) and GLUT9 (1.60 μM)
• Reports a 82.4% reduction in serum uric acid levels in hyperuricemic mice
• Provides pharmacokinetic data with bioavailability (F) of 33.71%

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download

Provenance

Source

figshare

Collection Method

Scaffold hopping and structure-guided design of 46 novel derivatives.

Freshness

Last updated 2026-05-06 16:08:14; freshness should be verified